Skip to main content

An update on an incident involving one of our systems

Hide
Quest Diagnostics

The Prevalence of Other Additive Novel Psychoactive Substances and Polydrug Positivity in Clinical Urine Specimens

AAFS 2026

American Academy of Forensic Science

New Orleans, LA, Feb 9-14, 2026

Oral presentation: The Prevalence of Other Additive Novel Psychoactive Substances and Polydrug Positivity in Clinical Urine Specimens

Authors: Neifeld J, Meli TM, Bland AA, Smith MP, Bartock SH

Medical Specialty: Prescription Drug Monitoring, Toxicology

Related content

Audio Podcast
Novel Psychoactive Substances (NPS): A Dangerous, Widespread Public Health Issue
On-Demand Webinar
The Growing Crisis of Novel Psychoactive Substances
Test FAQ
Novel Psychoactive Substances (NPS) Panel
Audio Podcast
Pharmacogenomics in Mental Health and Addiction

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.